**CURRENT POSITION:** Director

Institute for Therapeutic Innovation

 Tenured Professor of Medicine

 University of Florida

 6550 Sanger Road

 Lake Nona, FL 32827

 (ofc) 407-313-7060

 (mobile) 518-281-7170

 gdrusano@ufl.edu

**EDUCATION:** B.S. Degree (Physics), Boston College

 Chestnut Hill, Massachusetts, September 1967 - June 1971

 M.D. Degree, University of Maryland School of Medicine Baltimore, Maryland, September 1971 - June 1975

 Division of Infectious Diseases, University of Maryland School of Medicine

 Baltimore, Maryland, July 1973 - May 1975

 Straight Medical Internship, University of Maryland Hospital

 Baltimore, Maryland, July 1, 1975 - June 30, 1976

 Junior Assistant Resident in Medicine, University of Maryland Hospital Baltimore, Maryland, July 1, 1976 - June 30, 1977

 Assistant Resident in Medicine, University of Maryland Hospital

 Baltimore, Maryland, July 1, 1977 - June 30, 1978

 Chief Resident in Medicine, University of Maryland Hospital

 Baltimore, Maryland, July 1, 1979 - June 30, 1980

Fellow in Medicine in Infectious Diseases, University of Maryland Hospital Baltimore, Maryland, July 1, 1978-June 30, 1979, July 1, 1980-June 30, 1981

**CERTIFICATIONS & LICENSURES:**

 Diplomate, National Board of Medical Examiners, 1976

 State of Maryland, 1976; State of New York, 1993

 American Board of Internal Medicine, Certified 1978

**MAJOR RESEARCH/INTERESTS:**

 1. Drug pharmacology and response

 2. Multiple model adaptive control/Stochastic optimal sampling

 3. Modeling of antiviral chemotherapy

 4. Basic mechanisms of emergence of resistance for bacteria and HIV

**FACULTY APPOINTMENTS:**

 Instructor in Medicine, University of Maryland School of Medicine

 Baltimore, Maryland, July 1979 -1981

 Assistant Professor of Medicine, Division of Infectious Diseases

 University of Maryland School of Medicine, July 1, 1981 - 1986

Assistant Professor of Pharmacy, University of Maryland

School of Pharmacy Sept 1985 - June 1987

Associate Professor of Medicine, Division of Infectious Diseases

 University of Maryland School of Medicine, July 1, 1986 - June 30, 1992

 Associate Professor of Pharmacy, University of Maryland

 School of Pharmacy June 1987 - June 30, 1992

 Associate Professor of Microbiology and Immunology

 University of Maryland School of Medicine, July 1, 1991 - June 30, 1992

 Professor of Medicine, Division of Infectious Diseases

University of Maryland School of Medicine, July 1, 1992 - August 31, 1992

 Professor of Medicine and Director, Division of Clinical Pharmacology

 Albany Medical Center Hospital, September 1, 1992 - August 4, 2011

 Co-Director, Ordway Research Institute, July 1, 2005 – August 4, 2011

2011-Present Director, Institute for Therapeutic Innovation, College of Medicine, University of Florida

**MEDICAL SOCIETIES:**

 Fellow, Infectious Diseases Society of America

Member, American Federation for Clinical Research

**HONORS AND**  Boston College:

**AWARDS:** Scholar of the College of Arts and Sciences

Honors Program

Magna Cum Laude

 Phi Beta Kappa

University of Maryland School of Medicine:

Cum Laude

Alpha Omega Alpha

Received Rhone-Poulenc Award at International Congress of Chemotherapy, Berlin, 1991 for most innovative research with fluoroquinolones

American Society of Health System Pharmacy Research and Education

 Foundation 1998 Drug Therapy Research Award for an outstanding

 contribution to the scientific pharmaceutical literature

 Japanese Society of Chemotherapy: 1999 Plenary Lecture

President, International Society for Anti-Infective Pharmacology, 2000-2002

Executive Committee, International Society of Chemotherapy, 2003-2007

**Distinguished Investigator, American College of Clinical Pharmacology, 2003**

**Fellow, American Academy of Microbiology, 2009**

**Communicating Chair Gordon Conference “New Antibacterial Drug Discovery and Development” 3/14-3/19/2010**

**Recipient, Maxwell Finland Award for Scientific Excellence from the National Foundation for Infectious Diseases, 2012**

**Recipient, Cubist-ICAAC Award from the American Society for**

**Microbiology, 2013**

**Recipient, Paul Ehrlich Magic Bullet Award from Paracelsus University, Nurnberg, Germany, 2015**

**Recipient, University of Florida Research Foundation Professorship May, 2018**

**EDITORIAL APPOINTMENTS:**

Editor, Section of Pharmacology and Experimental Therapeutics,

Antimicrobial Agents and Chemotherapy, 1/89 -12/97

Editor, Mbio 1/1/10 – 12/31/15

 Reviewer for:

 New England Journal of Medicine

 Annals of Internal Medicine

 Archives of Internal Medicine

 American Journal of Medicine

 Journal of Infectious Diseases

 Journal of Antimicrobial Chemotherapy

 Antiviral Research

 Journal of the American Medical Association

Appointment to the Subcommittee on Guidelines for Bacteremia and Endocarditis, Antimicrobial Agents Use Committee, Infectious Diseases Society of America/ Food and Drug Administration, 11/88 -

**COMMITTEE SERVICE:**

 **Local:** 1. Human Volunteer Research Committee, University of Maryland, June 1984 to 1991.

 2. Committee on Research Involving Human Subjects, Albany Medical Center Hospital, December 1994 - 1999

 3. Antibiotic Task Force, Albany Medical Center Hospital, September 1994 - 2008

 4. Scientific Advisory Board, Albany Medical Center Hospital, November 1994 - 2008

 **National:**

1. Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC) Program Committee (National Infectious Disease Meeting).

2. National Institutes of Allergy and Infectious Diseases Ad Hoc Review Group for Drug Discovery for Opportunistic Infection.

3. National Institutes of Allergy and Infectious Diseases Ad Hoc Review Group for Models for Antiretroviral Therapy in Pregnancy.

 4. National Human Retroviruses and Related Infections Conference Program Committee.

1. IDSA Antibiotic Use and Clinical Trials Committee
2. *Ad Hoc* appointment NIAID Council (DMID) (September 18, 2006)
3. IDSA Annual Meeting Program Committee
4. *Ad Hoc* appointment NIAID Council (DMID) (May 21, 2007)
5. NIH Director’s New Innovator Award Review Group
6. NIH RC4 Second Level Review Group “Distinguished Editors”
7. IDSA Antimicrobial Resistance Committee
8. Workgroup on Anthrax Clinical Guidelines. Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults.

**International:**

1. Global Antimicrobial Research and Development Partnership (GARDP) Scientific Advisory Committee, part of Drugs for Neglected Diseases international (DNDi), a part of the World Health Organization

**GRANT SUPPORT:**

**Active:** **ACTIVE**

**Ongoing Research Support**

NIH/NIAID P01AI123036 Drusano & Louie (PIs) 8/2016 – 7/2021

“Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis.” Applies novel mathematical models to data derived from state-of-the-art hollow fiber infection model (HFIM) and murine infection models to develop highly active short-course combination drug regimens that maximize cure rates for tuberculosis.

Role: Contact PI

NIH/NIAID R01AI121430 Drusano & Louie (PIs) 12/2015 – 11/2020

Rapid Identification of Optimal Combination Regimens for *Pseudomonas aeruginosa*.

Goal: propose a novel method for identifying optimal combination therapy to maximize kill and suppress resistance to improve patient outcome.

Role: Contact PI

R01 AI111970 Brown & Drusano (PIs) 4/1/2014-3/31/2019

Optimizing Combination Therapy for Hepatitis C virus with pharmacodynamics models

Goal: employ an in vitro pharmacodynamic model for HCV infection, in conjunction with novel and innovative mathematical models, to elucidate optimal dosage regimens for combinations of direct-acting antiviral agents against HCV that will maximize resistance suppression and HCV inhibition.

Role: MPI

Evolva Subcontract with Defense Treat Reduction Agency (DTRA)

 Drusano (PI) 8/1/2014-3/31/2018

*In vitro* Pharmacodynamic Studies for the Evaluation of the Activity of the Investigational Compound GC‐072 against *Burkholderia pseudomallei* using an *In vitro* Hollow Fiber Infection Model and a Murine Aerosol Challenge Model.

Goal: Identify the dynamically-linked index for cell kill and resistance suppression for a new agent for B. pseudomallei in the hollow fiber system and then validate this in a murine aerosol challenge system.

Role: PI

**Finished:**

R01 AI090802 Drusano & Louie (PIs) 4/1/2010-3/31/2017 Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agents

Goal: to optimize the development of new aminoglycoside antibiotics (neoglycosides) to treat multi-resistant organisms.

Role: Contact PI

R56 AI111974 Louie & Drusano (PIs) 8/2014 – 4/2017

Combination Therapy Modeling for M tuberculosis Resistance Suppression and Kill.

Goal: to identify the dosages and frequencies of administration of drugs that optimizes the killing of M. tuberculosis in 3 metabolic states and will prevent emergence of resistance when the drugs are used alone and in combination, improve treatment outcomes for drug-susceptible and multidrug resistant M. tuberculosis and prevent emergence of resistance to the prescribed drugs.

Role: MPI

Bill and Melinda Gates Foundation Drusano (PI) 12/2007-12/2010

TB Drug Accelerator Program.

Goal: Investigate new approaches in TB drug research and development.

Role: PI

P01 AI060908-01A1 Drusano (PI) 7/15/05-12/31/10

Choosing Drug Doses for Biodefense Pathogens

Goal: Optimization dosing regimen to increase therapeutic efficacy in selected pathogens.

Role: PI

R01 AI079729 Drusano (PI) 6/1/2008-5/31/2012

Resistance Suppression for Influenza Virus with Combination Chemotherapy

Goal: Explore novel combination chemotherapy against influenza virus.

Role: PI

R01 AI079578 Drusano (PI) 5/1/2008-4/31/2012

Resistance Suppression for *P. aeruginosa* using Novel Combination Therapy Modeling

Goal: Employing Reduce *P. aeruginosa* resistance by using drug combinations to suppress resistance.

Role: PI

HHSN272201000043C Drusano (PI) 9/23/2010-9/22/2016

Broad Agency Announcement: BAA-NIAID-DMID-NIHAI2009058

Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance.

Goal: Test hypothesis that combination therapy suppresses resistance for non-fermenting organisms for VABP patients.

Role: PI

Supplement through Lifespan/Tufts/Brown Center for AIDS Research (CFAR). Efficacy of Oxazolidinones Alone and In *In vitro* EBA Studies In Polydrug TB Therapy. 08/08/2014-08/07/2015 Direct Costs: $107,519.00 Total costs: $161,279.00 G.L. Drusano, M.D. Co-Investigator. 2% Effort.

**BOOK EDITOR:**

1. Antimicrobial Pharmacodynamics in Theory and Clinical Proactice. Second Edition. Informa Healthcare, New York and London, 2007. Nightengale CH, Ambrose PG, Drusano GL, Murakawa T, Editors.

**BOOK CHAPTERS:**

 1. Calia, F.M., Drusano, G.L. Chapter 53. Emergency Diagnosis and Management of Infectious Diseases in Principles and Practice of Emergency Medicine, 2nd Edition; W.B. Saunders Co., Philadelphia, London, Toronto, 1984.

 2. Drusano, G.L. Pharmacokinetics of the Quinolone Antimicrobial Agents. In: Wolfson, J.S., Hooper, D.C., eds. Quinolone Antimicrobial Agents. Washington, D.C.: American Society for Microbiology, 1989:71-105.

 3. Drusano, G.L. Bacterial Pathogens for the 90's: A Case for New Drug Development. Editors: Georgopapadakou, N. & Sutcliffe, J. Emerging Targets in Antibacterial and Antifungal Chemotherapy. New York, New York. Routledge, Hall and Chapman, 1992:24-36.

 4. Karabulut N. and Drusano G.L. Pharmacokinetics of the Quinolone Antimicrobial Agents. In: Hooper D.C., Ed. Quinolone Antimicrobial Agents. Washington D.C.: American Society for Microbiology, 1993.

 5. Drusano G.L. Pharmacology of Anti-Infective Agents. In: Mandel G., Douglas R.G. and Bennett J.E., Eds. Principles and Practice of Infectious Diseases. New York, New York; Churchill Livingstone, 1994.

 6. West B.C. and G.L. Drusano. Critical Care Antimicrobials: Choose and Use. In: Sivak, E.D., Ed. The High Risk Patient: Management of the Critically Ill.

7. Killian AD, Kanyok TP, Drusano GL. Pharmacokinetics of Drugs Used for the Therapy of Mycobacterium avium-Complex Infection. In: Mycobacterium avium-Complex Infection. Progress in Research and Treatment. New York, New York ; Marcel Dekker, Inc:1996.

8. Drusano GL. Human Pharmacodynamics of Anti-Infectives: Determination from Clinical Trial Data. Chapter 14. In Antimicrobial Pharmacodynamics in Theory and in Clinical Practice. Marcel Dekker and Co. Nightingale, Murakawa and Ambrose, Eds.

9. Drusano GL, SL Preston and PJ Piliero. Pharmacodynamics of Antivirals.Chapter 12, pp 259-284. In Antimicrobial Pharmacodynamics in Theory and in Clinical Practice. Marcel Dekker and Co. Nightingale, Murakawa and Ambrose, Eds.

1. Drusano GL. Pharmacodynamics of Antivirals.Chapter 12, pp 295-314. In Antimicrobial Pharmacodynamics in Theory and in Clinical Practice, Second Edition. Informa Healthcare. Nightingale, Ambrose, Drusano and Murakawa, Eds.
2. Drusano GL. Human Pharmacodynamics of Anti-Infectives: Determination from Clinical Trial Data. Chapter 20, pp411-432. In Antimicrobial Pharmacodynamics in Theory and in Clinical Practice, Second Edition.Informa Healthcare. Nightingale, Ambrose, Drusano and Murakawa, Eds.
3. Forrest A and Drusano GL.Modeling of Toxicities Due to Antibiotics. Chapter 22, pp 449-462. In Antimicrobial Pharmacodynamics in Theory and in Clinical Practice, Second Edition.Informa Healthcare. Nightingale, Ambrose, Drusano and Murakawa, Eds.
4. Drusano GL and Craig WA. Antibacterial Chemotherapy. Section 295. Pp 1803-1814. In Goldman’s Cecil Medicine. 24th Edition. Copyright 2012. Elsevier Saunders; Philadelphia, PA. Goldman and Schafer, Eds.
5. Drusano, G.L. and A.N. Brown.  2014.  Pharmacometrics in Viral Infections.  In Schmidt, S. and Derendorf, H. (ed), Applied Pharmacometrics, AAPS Advances in the Pharmaceutical Sciences Series, Vol. 14. Springer, New York, New York.
6. Drusano GL. Antibacterial Chemotherapy. In Goldman’s Cecil Medicine. 25th Edition. Copyright 2015. Elsevier Saunders; Philadelphia, PA. Goldman and Schafer, Eds.

**ARTICLES:**

1. Hansen, S.L., Swomley, P., Drusano, G.: Effect of Carbon Dioxide and pH on Susceptibility of Bacteroides fragilis Group to Erythromycin. Antimicrobial Agents and Chemotherapy, 19(2):335-336, 1981.

2. Saah, A.J., Drusano, G.L., Warren, J.W., Tenney, J.H., Caplan, E.S.: Cefoxitin-Resistant Facultative or Aerobic Gram-Negative Bacilli in Infections Associated with the Gastrointestinal Tract. Annals of Internal Medicine 1981; 94(4):487-488.

3. Clements, M.L., Levine, M.M., Black, R.E., Robins-Browne, R., Cisneros, L., Lanata, C.F., Saah, A.J., Miller, E.H., Drusano, G.L.: Lactobacillus Prophylaxis for Diarrhea Due to Enterotoxigenic Escherichia coli. Antimicrobial Agents and Chemotherapy 1981; 29:104-108.

4. Saah, A., Koch, T., Drusano, G.: Falsely Elevated Creatinine Levels in Patients Receiving Cefoxitin. J.A.M.A. 1982; 247:205.

5. Standiford, H.C., Drusano, G.L., McNamee, W.B., Tatem, B., Ryan, P.A., Schimpff, S.C.: Comparative Pharmacokinetics of Moxalactam, Cefoperazone and Cefotaxime. Reviews of Infectious Diseases 1982; 4S:S585-SS594.

6. Drusano, G.L., Warren, J.W., Saah, A.J., Caplan, E.S., Tenney, J.H., Hansen, S., Granados, J., Standiford, H.C., Miller, E.H. Jr. A Prospective Randomized Controlled Trial of Cefoxitin versus Clindamycin-Aminoglycoside in Mixed Anaerobic-Aerobic Infections. Surgery, Gynecology and Obstetrics 1982; 154:715-720.

7. Drusano, G.L., Ryan, P.A., Standiford, H.C., Moody, M.R., Schimpff, S.C.: Integration of Selected Pharmacologic and Microbiologic Properties of Three New Beta-Lactam Antibiotics: A Hypothesis for Rational Comparison. Reviews of Infectious Diseases 1984; 6:357-363.

 8. McNamee, W.B., Drusano, G.L., Standiford, H.C., Tatem, B., Schimpff, S.C. The Serum Bactericidal activities of Latamoxef (Moxalactam), Cefoperazone and Cefotaxime. Journal of Antimicrobial Chemotherapy 1984; 14:491-497.

9. Drusano, G.L., Schimpff, S.C., Hewitt, W.L. The Acylampicillins: Mezlocillin, Piperacillin, and Azlocillin. Reviews of Infectious Diseases 1984; 6:13-32.

10. Kroll, M.H., Koch, T.R., Drusano, G.L., Warren, J.W. Lack of Interference with Creatinine Assays by Four Cephalosporin-Like Antibiotics. American Journal of Clinical Pathology 1984; 82:214-216.

11. Bustamante, C.I., Drusano, G.L., Tatem, B.A., Standiford, H.C. Postantibiotic Effect of Imipenem against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1984; 26:678-682.

12. Standiford, H.C., Drusano, G.L., Fitzpatrick, B., Tatem, B. Bacterial Activity of Ceftazidime in Serum Compared with That of Ticarcillin Combined with Amikacin. Antimicrobial Agents and Chemotherapy 1984; 26:339-342.

13. Drusano, G.L., Standiford, H.C., Bustamante, C.I., Rivera, G., Forrest, A., Leslie, J., Tatem, B., MacGregor, R.R., Schimpff, S.C.: Multiple Dose Pharmacokinetics of Imipenem/ Cilastatin (MK787/791). Antimicrobial Agents and Chemotherapy 1984; 26: 715-721.

14. Drusano, G.L., Standiford, H.C., Fitzpatrick, B., Leslie, J., Tangtatsawasdi, P., Ryan, P., Tatem, B., Moody, M.R., Schimpff, S.C. Comparison of the Pharmacokinetics of Ceftazidime and Moxalactam and Their Microbiological Correlates in Volunteers. Antimicrobial Agents and Chemotherapy 1984; 26:388-393.

15. Drusano, G.L., Forrest, A., Fiore, D., Auger, F., Caplan, E.S.: Effect of Saturable Clearance During High-Dose Mezlocillin Therapy. Antimicrobial Agents and Chemotherapy 1984; 26:686-688.

16. Drusano, G.L., Standiford, H.C., Bustamante, C.I., Forrest, A., Rivera, G., Tatem, B., Schimpff, S.C.: The Plasma Pharmacokinetics of High Dose (1 Gram) Imipenem Co-administered with 1 Gram of Cilastatin in Six Normal Volunteers. European Journal of Clinical Microbiology 1984; 3:468-470.

17. Fiore, D., Auger, F.A., Drusano, G.L., Dandu, V.R., and Lesko, L.J.: Improved Micromethod for Mezlocillin Quantitation in Serum and Urine by High Pressure Liquid Chromatography. Antimicrobial Agents and Chemotherapy 1984; 26:775-777.

18. Drusano, G.L., de Jongh, C., Newman, K., Joshi, J., Wharton, R., Moody, M.R., Schimpff, S.C. Moxalactam and Piperacillin: A Study of In vitro Characteristics and Pharmacokinetics in Cancer Patients. Infection 1985; 13:20-26.

19. Viollier, A.F., Standiford, H.C., Drusano, G.L., Tatem, B.A., Moody, M., and Schimpff, S.C.: Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, with and without Gentamicin. Journal of Antimicrobial Chemotherapy 1985; 15:597-606.

1. Drusano, G.L., Standiford, H.C., Bustamante, C.I., Rivera, G., Forrest, A., Leslie, J., Tatem, B., Delaportas, D., Schimpff, S.C. Safety and Tolerability of Multiple Doses of Imipenem/Cilastatin. Clinical Pharmacology and Therapeutics. 1985; 37:539-543.
2. Wade, J.C., Standiford, H.C., Drusano, G.L., Johns on, D.E., Moody, M.R., Bustamante, C.I., Joshi, J.H., deJongh, C., Schimpff, S.C. Potential of Imipenem as Single Agent Empiric Antibiotic Therapy of Febrile Neutropenic Cancer Patients. American Journal of Medicine 1985; 78 (Suppl 6A):62-72.
3. Drusano, G.L., Standiford, H.C. The Pharmacology of Imipenem/Cilastatin in Normal Volunteers. American Journal of Medicine 1985; 78 (Suppl 6A):47-53.

21. Gonzalez, M.A., Moranchel, A.H., Duran, S., Pichardo, A., Magana J.L., Painter B., Drusano, G.L. Multiple-Dose Ciprofloxacin Dose Ranging and Kinetics. Clinical Pharmacology and Therapeutics 1985; 37:633-637.

22. Drusano, G.L., Joshi, J., Forrest, A., Ruxer, R., Standiford, H., Leslie, J., Wade, J., Schimpff, S.C. The Serum Pharmacokinetics of Ceftazidime Alone or in Combination with Either Piperacillin or Tobramycin in Cancer Patients. Antimicrobial Agents and Chemotherapy 1985; 27:605-607.

23. Gonzalez, M.A., Moranchel, A.H., Duran, S., Pichardo, A., Magana, J.L., Painter, B., Forrest, A., Drusano, G.L. Multiple Dose Pharmacokinetics of Ciprofloxacin Administered Intravenously to Normal Volunteers. Antimicrobial Agents and Chemotherapy 1985; 28:235-239.

24. Morris, J.G., Tenney, J.H., Drusano, G.L. In Vitro Susceptibility of Pathogenic Vibrio Species to Norfloxacin and Six Other Antimicrobial Agents. Antimicrobial Agents and Chemotherapy 1985; 28:442-445.

25. Khabbaz, R.F., Standiford, H.C., Bernstein, D., Nipper, H.C., Tatem, B.A., Smalls, U., Drusano, G.L., Caplan, E. Measurement of serum amikacin by a latex agglutination inhibition test. Journal of Clinical Microbiology 1985; 22:699-701.

26. Drusano, G.L., Standiford, H.C., Ryan, P.A., McNamee, W.B., B. Tatem, Schimpff, S.C. Correlation of Predicted Serum Bactericidal Activities and Values Measured in Volunteers. European Journal of Clinical Microbiology 1986; 5:88-92.

27. Schimpff, S.C., Drusano, G.L., Standiford, H.C. Serum Bactericidal Test in Volunteers - A Review. European Journal of Clinical Microbiology 1986; 5:71-78.

28. Drusano, G.L. An overview of the pharmacology of imipenem/cilastatin. Journal of Antimicrobial Chemotherapy 1986; 18 (Suppl E):79-92.

29. deJongh, C.A., Joshi, J.H., Thompson, B.W., Newman, K.A., Finley, R.S., Moody, M.R., Salvatore, P.C., Tenney, J.H., Drusano, G.L., Schimpff, S.C. A Double Beta-Lactam Combination Versus An Aminoglycoside-Containing Regimen As Empiric Antibiotic Therapy For Febrile Granulocytopenic Cancer Patients. American Journal of Medicine 1986; 80:101-104.

30. Standiford, H.C., Drusano, G.L., Bustamante, C., Forrest, A., Rivera, G., Tatem, B. Imipenem: Coadministered with cilastatin compared with moxalactam: Integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. Antimicrobial Agents and Chemotherapy 1986; 29:412-417.

31. Joshi, M., Anthony W.C., Tenney, J.H., Drusano, G.L., Caplan, E.S., Standiford, H.C., Henson, A., and Warren, J.W. Double blinded, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections. Antimicrobial Agents and Chemotherapy 1986; 30:90-95.

32. Drusano, G.L., Townsend, R.J., Walsh, T.J., Forrest, A., Antel, E.J. Steady State Serum Pharmacokinetics of Novobiocin and Rifampin Alone and in Combination. Antimicrobial Agents and Chemotherapy 1986; 30:42-45.

33. Drusano, G.L., Standiford, H.C., Plaisance, K., Forrest, A., Leslie, J., Caldwell, J. Absolute oral bioavailability of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1986; 30:444-446.

34. Drusano, G.L., Plaisance, K.I., Forrest, A., Standiford, H.C. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1986; 30:440-443.

35. Drusano, G.L. An overview of the pharmacology of intravenously administered ciprofloxacin. American Journal of Medicine 1987; 82 (Suppl 4A):339-345.

36. Bustamante, C.I., Drusano, G.L., Wharton, R.C., Wade, J.C. Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrobial Agents and Chemotherapy, 31:632-634, 1987.

37. Drusano, G.L., Weir, M., Forrest, A., Plaisance, K., Emm, T., Standiford, H.S. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy 1987; 31:860-864.

38. Plaisance, K.I., Drusano, G.L., Forrest, A., Bustamante, C.I., Standiford, H.C. Effect of dose size on bioavailability of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1987; 31:956-958.

39. Standiford, H.C., Drusano, G.L., Forrest, A., Tatem, B., Plaisance, K.I. Bactericidal activity of ciprofloxacin compared to cefotaxime in normal volunteers. Antimicrobial Agents and Chemotherapy 1987; 31:1177-1182.

40. Drusano, G.L., Plaisance, K.I., Forrest, A., Bustamante, C., Devlin A., Standiford, H.C., Wade, J.C. Steady state pharmacokinetics of imipenem as determined in febrile neutropenic cancer patients. Antimicrobial Agents and Chemotherapy 1987; 31:1420-1422.

41. Lynch, M.J., Drusano, G.L., Mobley, H.L.T. Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1987; 31:1892-1896.

42. Drusano, G.L., Muncie, Jr., H.L., Hoopes, J.M., Damron, D.J., Warren, J.W. Commonly used methods of estimating creatinine clearance are inadequate for elderly debilitated nursing home patients. Journal of the American Geriatrics Society 1988; 36:437-441.

43. Drusano, G.L. The role of pharmacokinetics in the outcome of infections. Antimicrobial Agents and Chemotherapy 1988; 32:289-297.

44. Ferreccio, C., Morris, Jr., J.G., Valdivieso, C., Prenzel, I., Sotomayor, V., Drusano, G.L., Levine, M.M. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. Journal of Infectious Diseases 1988; 157:1235-1238.

45. Drusano, G.L., Forrest, A., Snyder, M.J., Reed, M.D., Blumer, J.L. An evaluation of optimal sampling strategy and adaptive study design. Clinical Pharmacology and Therapeutics 1988; 44:232-238.

46. Forrest, A., Weir, M., Plaisance, K.I., Drusano, G.L., Leslie, J., Standiford, H.C. Relationships between renal function and disposition of oral ciprofloxacin. Antimicrobial Agents and Chemotherapy 1988; 32:1537-1540.

47. Margaret, B.S., Drusano, G.L., Standiford, H.C. Emergence of resistance to carbapenem antibiotics in *Pseudomonas aeruginosa*. Journal of Antimicrobial Chemotherapy 1989; 24(suppl. A):161-167.

48. Drusano, G.L., Forrest, A., Plaisance, K.I., Wade, J.C. A prospective evaluation of optimal sampling theory in the determination of the steady state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clinical Pharmacology and Therapeutics 1989; 45:635-641.

49. Plaisance, K.I., Drusano, G.L., Forrest, A., Townsend, R.J., Standiford, H.C. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrobial Agents and Chemotherapy 1989; 33(5):618-620.

50. Yuen, G.J., Drusano, G.L., Forrest, A., Plaisance, K.I., Caplan, E.S. Prospective use of optimal sampling theory: Steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients. Clinical Pharmacology and Therapeutics 1989; 46(4):451-457.

51. Yuen, G.J., Plaisance, K.I., Forrest, A., Caplan, E.S., Drusano, G.L. Pharmacokinetics of ciprofloxacin in trauma patients. Reviews of Infectious Diseases 1989; 11(5):S1021-S1022 (extended abstract).

52. Yuen GJ, GL Drusano, K Plaisance, A Forrest and ES Caplan. Ciprofloxacin pharmacokinetics in critically ill trauma patients. Am J Med 1989;87(5A):70S-75S.

53. Plaisance, K.I., Drusano, G.L., Forrest, A., Weir, M.R., Standiford, H.C. Effect of renal function on the bioavailability of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1990; 34:1031-1034.

54. Gitterman, S.R., Drusano, G.L., Egorin, M.J., Standiford, H.C. and the Veterans Administration Clinical Trials Group. Population pharmacokinetics of zidovudine. Clinical Pharmacology and Therapeutics 1990; 48:161-167.

55. Drusano, G.L. Human Pharmacodynamics of Beta-lactams, Aminoglycosides and their Combination. Scand J Infect Dis, (Suppl) 74:235-248. 1991.

56. Drusano, G.L. Optimal sampling theory and population modeling: Application to determination of the influence of the microgravity environment on drug distribution and elimination. Journal of Clinical Pharmacology 1991; 31:962-967.

57. Drusano, G.L., Yuen, G.J., Lambert, J.S., Seidlin, M., Dolin, R., Valentine, F.T. Quantitative relationships between dideoxyinosine exposure and surrogate markers of response in a phase I trial. Annals of Internal Medicine 1992;116:562-566.

58. Hamilton, J.D., Hartigan, P.M., Simberkoff, M.S., Day, P.L., Diamond, G.R., Dickinson, G.M., Drusano, G.L., Egorin, M.J., George, W.L., Gordin, F.M., Hawkes, C.A., Jensen, P.C., Kilmas, N.G., Labriola, A.M., Lahart, C.J., O'Brien, W.A., Oster, C.N., Weinhold, K.J., Wray, N.P., Zolla-Pazner, S.B., and the Veterans Affairs Cooperative Study Group on AIDS Treatment. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. New England Journal of Medicine 1992; 326:437-443.

59. Drusano, G.L., Yuen, G.J., Morse, G., Cooley, T.P., Seidlin, M., Lambert, J.S., Liebman, H.A., Valentine, F.T. and Dolin, R. Impact of bioavailability on the determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials. Antimicrobial Agents and Chemotherapy 1992;36:1280-1283.

60. Yuen, G.J., Drusano, G.L., Brooks, J., Flor, S. Use of nonlinear, mixed-effects modeling for population analysis of ofloxacin: Effects of age on oral drug pharmacokinetics. Pharmacotherapy 1992; 12 (2) 88-92.

61. Wilson WR, DN Gilbert, AL Bisno, LR Freedman, C Smith, G Drusano and D Kaye. Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992 (Suppl 1);15:S89-S95.

62. Kort, J.J., Bilello, J.A., Bauer, G. and Drusano, G.L.. Preclinical evaluation of antiviral activity and toxicity of Abbott (A)-77003, an inhibitor of the Human Immunodeficiency Virus Type 1 protease. Antimicrobial Agents and Chemotherapy 1993:37: 115-119.

63. Drusano G.L., Johnson D.E., Rosen M., and Standiford H.C. Pharmacodynamics of a fluoroquinolone antimicrobial in a neutropenic rat model of Pseudomonas sepsis. Antimicrobial Agents and Chemotherapy 1993;37:483-490.

64. Standiford HC, Walsh TJ, Drusano GL, Tatem BA and Townsend RJ. Serum inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus in volunteers receiving novobiocin and rifampin alone and in combination. Diagn Microbiol Infect Dis 1993;17:135-142.

65. Drusano GL. Pharmacodynamics of antiretroviral chemotherapy. Infection Control & Hospital Epidemiology 1993;14:530-536.

66. St. Clair MH, PM Hartigan, JC Andrews, CL Varro, MS Simberkoff, JD Hamilton and the VA Cooperative Study Group.Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J Acquired Imm Def Syndr 1993;6:891-897.

67. Trifillis, A.L., X. Cui and G.L. Drusano. Use of human renal proximal tubule cell cultures to study foscarnet induced nephrotoxicity in-vitro. Antimicrobial Agents and Chemotherapy 1993; 37: 2496-2499.

68. Drusano GL, Forrest A, Yuen JA and Plaisance KI. Optimal Sampling Theory: Effect of error in a nominal parameter value on bias and precision of parameter estimation. Journal of Clinical Pharmacology 1994;34:967-974.

69. Bilello JA, Eiseman JL, Standiford HC and Drusano GL. Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy. Antimicrob Agents Chemother 1994;38:628-631.

70. Drusano GL, Balis FM, Gitterman SR and Pizzo PA. Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob Agents Chemothe*r* 1994;8:1726-1731.

71. Bilello, J.A., Bauer, G., Dudley, M.N., Cole, G.A. & Drusano, G.L. The effect of 2',3' dideoxy-2',3' didehydrothymidine (D4T) in an in vitro hollow fiber pharmacodynamic model system correlates with results of dose ranging clinical studies. Antimicrobial Agents & Chemotherapy 1994;38:1386-1391.

72. Drusano, G.L. and Hutchison, M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995; 96:11-16.

73. Bilello, J.A., Bilello, P.A., Prichard, M., Robbins, T., and Drusano, G.L. Reduction of the in vitro activity of A 77003, an inhibitor of the Human Immunodeficiency Virus protease, by human serum 1 acid glycoprotein. Journal of Infectious Diseases 1995;171:546-551.

74. Drusano, G.L., Liu, W., Perkins, R., Madu, A., Madu, C., Mayers, M., and Miller, M.H. The determination of robust ocular pharmacokinetic parameters from the serum and vitreous humor of albino rabbits following the systemic administration of ciprofloxacin from sparse data sets, using IT2S, a population pharmacokinetic modeling program. Antimicrobial Agents and Chemotherapy 1995; *39:1683-7*.

75. Perkins, R.J., Liu, W., Drusano, G.L., Madu, A., Mayers, M., and Miller, M.H. Pharmacokinetics of ofloxacin in the serum and vitreous humor of albino and pigmented rabbits. Antimicrobial Agents of Chemotherapy 1995;39:1493-8.

76. Bilello, J.A., Bilello, P.A., Kort, J.J., Dudley, M.N., Leonard, J., and Drusano, G.L. Efficacy of constant infusion of A 77003, an inhibitor of the HIV protease in limiting acute HIV-1 infection *in vitro*. Antimicrobial Agents and Chemotherapy 1995; 39:2523-2527.

77. Yuen, G.J., Drusano, G.L., Fletcher, C., Capparelli, E., Connor, J.D., Lalezari, J.P., Drew, L., Follansbee, S.,Busch, D., Jacobson, M., Spector, S.A., Squires, K., and Buhles, W. Population differences in ganciclovir clearance as determined by non-linear mixed effects modeling. Antimicrobial Agents and Chemotherapy 1995;39:2350-2.

78. Preston SL, LL Briceland, BM Lomaestro, TS Lesar, GR Bailie and GL Drusano. Dosing adjustment of 10 antimicrobials for patients with renal impaiment. The Annals of Pharmacotherapy 1995;29:1202-1207.

79. Bilello, J.A., Bilello, P.A., Stellrecht, K., Leonard, J., Norrbeck, D., Kempf, D.J., Robbins, T., and Drusano, G.L. The uptake and anti-HIV activity of A 80987, an inhibitor of the HIV-1 protease, is reduced by human serum 1 - acid glycoprotein. Antimicrobial Agents and Chemotherapy 1996;40:1491-7.

80. Madu, A., Mayers, M., Perkins, R.J., Liu, W., Drusano, G.L., Aswani, R., Madu, C.N., and Miller, M.H. Aqueous and Vitreous penetration of ciprofloxacin following different modes of systemic administration. Exp Eye Res 1996;63:129-136.

81. Bilello, J.A., K. Stellrecht, G.L. Drusano and D.S. Stein. Soluble TNF receptor type II correlates with HIV RNA copy number in HIV-infected patients. Journal of Infectious Diseases 1996;173:464-467.

82. Stein, D.S., D.G. Fish, J.A. Bilello, J Chodakewitz, E. Emini, C. Hildebrand, S.L. Preston, G.L. Martineau, and G.L. Drusano. A 24 week open label phase I evaluation of the HIV protease inhibitor MK-639. AIDS 1996;10:485-92.

83. Stein DS, H Dunn and GL Drusano. Acute Thrombocytopenia secondary to the administration of the peptidomimetic HIV protease inhibitor MK-639 (L735524). AIDS 1996;10:678-680.

84. Drusano, G.L., F. Aweeka, J. Gambertoglio, M. Jacobson, M. Polis, H.C. Lane, C. Eaton and S. Martin-Munley. Relationship between foscarnet exposure, baseline Cytomegalovirus blood culture and the time to progression of Cytomegalovirus retinitis in HIV-positive patients. AIDS 1996;10:1113-1119.

85. Preston SL, Drusano GL. Non-Parametric expectation maximization (NPEM2) population modeling of ganciclovir. Journal of Clinical Pharmacology 1996;36:301-10.

86. Gruber SA, Gallichio M, Rosano TG, Hughes SE and Drusano GL. Comparative pharmacokinetics of cyclosporine A and cyclosporine G in renal allograft recipients. Transplant Proc. 1996;28:892.

87. Drusano GL, MN Prichard, PA Bilello and JA Bilello. Modeling combinations of antiretroviral agents *in vitro* with integration of pharmacokinetics: Guidance of regimen choice for clinical trial evaluation. Antimicrobial Agents and Chemotherapy 1996;40:1143-7.

88. Drusano GL and FW Goldstein. Relevance of the Alexander Project: pharmacodynamic considerations. J Antimicrob Chemother 1996;38 Suppl A:141-154.

89. Drusano G.L. and W.A. Craig. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother. 1997;9 Suppl 3:38‑44.

90. Preston SL, GL Drusano, AL Berman, CL Fowler, AT Chow, B Dornseif, V Reichl, J Natarajan, M Corrado. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Journal of the American Medical Association 279:125-129, 1998.

91. Liu, W., Perkins, R.J., Drusano, G.L., Madu, A., Aswani, R., Mayers, M., Mian, U., and Miller, M.H. Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: Physicochemical properties which regulate the penetration of quinolone antimicrobials. Antimicrob Agents Chemother 1998;42:1417-1423.

92. Stein DS and Drusano GL. Modeling of the change in CD4 lymphocyte cell counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir. Antimicrobial Agents and Chemotherapy 41:449-453, 1997.

93. Drusano GL and Stein DS. Mathematical modeling of the iterrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. Antimicrobial Agents and Chemotherapy 42:358-361, 1998.

94. Louie A, GL Drusano, P Banerjee, Q-F Liu, W Liu, P Kaw, M Shayegani, H Taber and MH Miller. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998;42:1105-1109.

95. Drusano GL, JA Bilello, DS Stein, M Nessly, A Meibohm, EA Emini, P Deutsch, J Condra, J Chodakewitz, and DJ Holder. Factors Influencing the Emergence of Resistance to Indinavir: Role of Virologic, Immunologic, and Pharmacologic Variables. J Infect Dis. 1998;178:360-367.

96. Hafner R, J Bethel, M Power, B Landry, M Banach, L Mole, HC Standiford, S Follansbee, P Kumar, R Raasch, D Cohn, D Mushatt and GL Drusano. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus‑infected volunteers. Antimicrob Agents Chemother. 1998; 42:631‑639.

97. Preston SL, GL Drusano, AL Berman, CL Fowler, AT Chow, B Dornseif, V Reichl, J Natarajan, FA Wong and M Corrado. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community‑acquired infection. Antimicrob Agents Chemother. 1998;42:1098‑1104.

98. McSharry JM, NS Lurain, GL Drusano, A Landay, J Manischewitz, M Nokta, M O’Gorman, HM Shapiro, A Weinberg, P Reichelderfer and C Crumpacker. Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates. J Clin Microbiol. 1998;36:958‑964.

99. Louie A, QF Liu, GL Drusano, W Liu, M Mayers, E Anaissie and MH Miller. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration‑time curve values which mimic those of high‑dose fluconazole in humans. Antimicrob Agents Chemother. 1998;42:1512‑1514.

100. Drusano GL, DZ D’Argenio, W Symonds, PA Bilello, J McDowell, B Sadler, A Bye and JA Bilello. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother. 1998;42:2153‑2159.

101. McSharry JM, NS Lurain, GL Drusano, A Landay, M Nokta, MR O’Gorman, A Weinberg, HM Shapiro, P Reichelderfer and C Crumpacker. Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates. Antimicrob Agents Chemother. 1998;42:2326‑2331.

102. Drusano G.L. Infection in the intensive care unit: beta‑lactamase‑mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. Clin Infect Dis. 1998;27 Suppl 1:S111‑116.

103. Drusano G, Labro MT, Cars O, Mendes P, Shah P, Sörgel F, Weber W. [Pharmacokinetics and pharmacodynamics of fluoroquinolones.](http://www.ncbi.nlm.nih.gov/pubmed/11869252) Clin Microbiol Infect. 1998;4 Suppl 2:S27-S41.

104. Skowron G, DS Stein, GL Drusano, K Melbourne, JA Bilello, D Mikolich, K Rana, JM Agosti, A Mongillo, J Whitmore and MJ Gilbert. The safety and efficacy of granulocyte-macrophage colony stimulating factor (sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: A randomized, double-blind, placebo-controlled trial. J Infect Dis 1999; 180:1064-1071.

105. Margolis D, A HerediaJ Gaywee, D Oldach, GL Drusano, R Redfield. Abacavir and mycophenolic acid, an inhibitor inhibitor of inosine monophospahte dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999;21:362-370.

106. Hafner R, CB Inderlied CB, DM Peterson, DJ Wright, HC Standiford, GL Drusano and K Muth. Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated *Mycobacterium avium* complex infections. J Infect Dis 1999;180:438-447.

107. Rybak MJ, BJ Abate, SL Kang, MJ Ruffing, SA Lerner and GL Drusano. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999:43:1549-1555.

108. Kashuba AD, AN Nafziger, GL Drusano and JS Bertino, Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999;43:623-29.

109. Preston SL, GL Drusano, P Glue, J Nash, SK Gupta, and P McNamara. Pharmacokinetics and absolute biavailability of ribavirin in healthy volunteers as determined by stable isotope methodology. Antimicrob Agents Chemother 1999;43:2451-2456.

110. Louie A, P Banerjee, GL Drusano, M Shayegani and MH Miller. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of *Candida albicans*. Antimicrob Agents Chemother 1999;43:2841-2847.

111. Louie A, W Liu, DA Miller, AC Sucke, QF Liu, GL Drusano, M Mayers and MH Miller. Efficacies of high dose fluconazole plus 5-fluorocytosine versus amphotericin, fluconazole and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to *Candida albicans*. Antimicrob Agents Chemother 1999;43:2831-2840.

112. Snyder S, DZ D’Argenio, O Weislow, JA Bilello and GL Drusano. The triple combination of indinavir, zidovudine plus lamivudine is highly synergistic. Antimicrob Agents Chemother. 2000;44:1051-1058.

113. Hanley EM, A Veeder, T Smith, G Drusano, E Currie and RA Venezia. Evaluation of an antiseptic triple lumen catheter in an intensive care unit. Crit Care Med 2000;28:366-370.

114. Drusano GL, DZ D’Argenio, SL Preston, C Barone, W Symonds, S LaFon, M Rogers, W Prince, A Bye and JA Bilello. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother 2000;44:1655-1659.

115. Drusano GL, SL Preston, M Van Guilder, D North, M Gombert, M Oefelein, L Boccumini, B Weisinger, M Corrado and J Kahn. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000;44:2046-2051.

116. Drusano GL. [Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome.](http://www.ncbi.nlm.nih.gov/pubmed/11131956) J Chemother. 2000 Oct;12 Suppl 4:21-26.

117. Drusano GL. [Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome.](http://www.ncbi.nlm.nih.gov/pubmed/11131956) J Chemother. 2000 Oct;12 Suppl 4:21-26.

118. Drusano GL, SL Preston, C Hardalo, R Hare, C Banfield, O Vesga, D Andes and WA Craig. Use of preclinical data for the choice of a Phase II/III dose for evernimicin with application to decision support for identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother. 2001;45:13-22.

119. Drusano GL, JA Bilello, SL Preston, E Omara, S Kaul, S Schnittman and R Echols. Hollow fiber unit evaluation of a new Human Immunodeficiency Virus (HIV) -1protease inhibitor, BMS 232632, for determination of the linked pharmacodynamic variable.J Infec Dis 2001;183:1126-1129.

120. Louie A. P Kaw, W Liu, N Jumbe, MH Miller and GL Drusano. Pharmacodynamics of daptomycin in a murine thigh model of *Staphylococcus aureus* infection. Antimicrob Agents Chemother 2001;45:845-851.

120. Hafner R, J Bethel, HC Standiford, S Follansbee, DL Cohn, RE Polk, L Mole, R Raasch, P Kumar, D Mushatt, G. Drusano. Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. Antimicrob Agents Chemother 2001;45:1572-1577.

121. Drusano GL, SL Preston, D Smee, K Bush, K Bailey, RW Sidwell. Pharmacodynamic evaluation of RWJ 270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza, predicts efficacy for once-daily dosing. Antimicrob Agents Chemother 2001;45:2115-2118.

122. McSharry JJ, A McDonough, B Olson, S Hallenberger, J Reefschaelger, W Bender and GL Drusano. Susceptibilities of Human Cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir. Antimicrob Agents Chemother 2001;45:2925-2927.

123. Drusano GL, SL Preston, MH Gottfried, LH Danziger and KA Rodvold. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2002;46:586-589.

124. Drusano GL, PA Bilello, WT Symonds, DS Stein, J McDowell, A Bye and JA Bilello. Pharmacodynamics of abacavir in an *in vitro* hollow-fiber model system. Antimicrob Agents Chemother 2002;46:464-470.

125. Drusano GL, KHP Moore, JP Kleim, W Prince and A Bye. Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through the use of population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2002;46:913-916.

126. Mouton JW, MN Dudley, O Cars, H Derendorf, GL Drusano. Standardization of pharmacokinetic/pharmacodynamic (PK/PD)terminology for anti-infective drugs. Int J Antimicrob Agents 2002;19:355-358.

127. Tam VH, PS McKinnon, RL Akins, MJ Rybak, GL Drusano. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002 Sep;50(3):425-428.

128. Hossain MM, Coull JJ, Drusano GL, Margolis DM. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 2002 Jul;55(1):41-52.

1. Kim M-J, AN Nafziger, CD Harro, HL Keyserling, KM Ramsey, GL Drusano, JS Bertino, Jr. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 2003;21:1174-1179.
2. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003:36 (Suppl 1):S42-50.
3. Tam VH, A Louie, BM Lomaestro, GL Drusano. Integration of population pharmacokinetics, a pharmacodynamic target and microbiological surveillance data to generate a rational empiric dosing strategy for cefepime against *Pseudomonas aeruginosa*. Pharmacotherapy 2003;23:291-295.
4. Piliero PJ, DG Fish, S Preston, D Cunningham, T Kinchelow, M Salgo, J Qian, GL Drusano. Guillain-Barre Syndrome associated with immune reconstitution. Clin Infect Dis. 2003;36:e111-114.
5. Preston SL, PJ Piliero, GL Drusano. Pharmacodynamics and clinical use of anti-HIV drugs. Infect Dis Clin North Am 2003;17:651-674.
6. Masterton R, G Drusano, DL Paterson, G Park. Appropriate antimicrobial treatment in nosocomial infections – the clinical challenges. J Hosp Infect 2003;55 (Suppl 1);1-12.
7. Tam VH, PS McKinnon, RL Akins, GL Drusano, MJ Rybak. Pharmacokinetics and pharmacodynamics of cefipime in patients with various degrees of renal function. Antimicrob Agents Chemother 2003;47:1853-1861.

# Jumbe N, A Louie, R Leary, W Liu, MR Deziel, VH Tam, R Bachhawat, C Freeman, JB Kahn, K Bush, M N Dudley, MH Miller, GL Drusano. Application of a mathematical model to prevent *in-vivo* amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112:275-285.

1. Tam VH, SL Preston, GL Drusano. Optimal sampling schedule design for populations of patients. Antimicrob Agents Chemother 2003;47:2888-2891.
2. Preston SL, PJ Piliero, JA Bilello, DS Stein, WT Symonds, GL Drusano. *In vitro*-*in vivo* model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours. Antimicrob Agents Chemother 2003;47:3393-3399.
3. Bradley JS, MN Dudley, GL Drusano. Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003;22:982-992.
4. Drusano GL Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003;36 (Suppl 1):S42-50.
5. Tam VH, Preston SL, Drusano GL. [Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling.](http://www.ncbi.nlm.nih.gov/pubmed/14695034) Pharmacotherapy. 2003;23:1545-1549.
6. Drusano GL and SL Preston. A 48 week duration of therapy with pegylated Interferon alfa-2b plus ribavirin may be too short to maximize long-term response for patients infected with genotype-1 Hepatitis C virus. J Infect Dis. 2004;189:964-970.
7. Drusano GL, SL Preston, C Fowler, M Corrado, B Weisinger, J Kahn. The relationship between fluoroquinolone AUC/MIC Ratio and the probability of eradication in patients with nosocomial pneumonia. J Infect Dis. 2004;189:1590-1597.
8. Drusano GL.Antimicrobial pharmacodynamics: the interactions between bug and drug. Nature Reviews: Microbiology. 2004;2:289-300.
9. Drusano GL. Editorial Commentary: “How Does a Patient Maximally Benefit from Antimicrobial Chemotherapy?”. Clin Infect Dis 2004;39:1245-1246.
10. McSharry JJ, AC McDonough, BA Olson, GL Drusano. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors. Clin Diag Lab Immunol. 2004;11:21-28.
11. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. [Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.](http://www.ncbi.nlm.nih.gov/pubmed/15476901) Clin Ther. 2004;26:1187-1198.
12. Ball AP, Bartlett JG, Craig WA, Drusano GL, Felmingham D, Garau JA, Klugman KP, Low DE, Mandell LA, Rubinstein E, Tillotson GS. [Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.](http://www.ncbi.nlm.nih.gov/pubmed/15565907) J Chemother. 2004;16:419-436.
13. Gumbo T, A Louie, MR Deziel, LM Parsons, M Salfinger, GL Drusano. Selection of a Moxifloxacin Dose that Suppresses *Mycobacterium tuberculosis* Resistance Using an In Vitro Pharmacodynamic Infection Model and Mathematical Modeling. J Infect Dis 2004;190:1642-1651.
14. Lodise TP, B Lomaestro, KA Rodvold, LH Danziger, GL Drusano. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004;48:4718-4724.
15. Lomaestro BM and GL Drusano. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005;49:461-463.
16. Mouton J, MN Dudley, O Cars, H Derendorf, GL Drusano. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005;55:601-607.
17. Kreuger WA, J Bullita, M Kinzig-Schippers, C Landersdorfer, U Holzgrabe, KG Naber, GL Drusano, F Sorgel. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005;49:1881-1889.
18. Drusano GL. Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy 2005;25:150S-158S.
19. Gumbo T, A Louie, MR Deziel, GL Drusano. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill, but to rapid emergence of resistance. Antimicrob Agents Chemother 2005;49:3178-3181.
20. Tam VH, A Louie, MR Deziel, W Liu, R Leary, GL Drusano. Bacterial Population Responses to Drug Selective Pressure: Examination of garenoxacin against Pseudomonas aeruginosa. J Infect Dis. 2005;192:420-428.
21. Lodise TP, SL Preston, V Barghava, A Bryskier, R Nusrat, S Chapel, M Rangaraju, GL Drusano. Pharmacodynamics of an 800 mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn Microbiol Infect Dis. 2005;52:45-52.
22. Blumer JL, MD Reed, EL Kaplan, GL Drusano. Explaining the poor bacteriological eradication rate of single-dose ceftriaxone in Group A streptococcal tonsillopharyngitis: A reverse engineering solution using pharmacodynamic modeling. Pediatrics 2005;116:927-932.
23. Hope WW, PA Warn, A Sharp, P Reed, B Keevil, A Louie, DW Denning, GL Drusano. Surface response modeling to examine the combination of amphotericin B and 5-fluorocytosine for invasive candidiasis. J Infect Dis. 2005;192:673-680.
24. A Louie, M Deziel, W Liu, MF Drusano, T Gumbo, GL Drusano. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother. 2005;49:5058-5068.
25. M Deziel, H. Heine, A Louie, M Kao, WR Byrne, J Bassett, L Miller, K Bush, M Kelley, GL Drusano. Identification of effective antimicrobial regimens for use in humans for the therapy of*Bacillus anthracis*infections and post-exposure prophylaxis. Antimicrob Agents Chemother 2005;49:5099-5106.
26. NL Jumbe, A Louie, MH Miller, W Liu, MR Deziel, VH Tam, R Bachhawat, GL Drusano. Quinolone efflux pumps play a central role in emergence of resistance to fluoroquinolones in *Streptococcus pneumoniae*. Antimicrob Agents Chemother. 2006;50:310-317.
27. GL Drusano, A Louie, M Deziel, T Gumbo. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis. 2006;42:525-532.
28. TP Lodise, DH Rhoney, VH Tam, PS McKinnon, GL Drusano. Pharmacokinetic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis. 2006;54:223-230.
29. M Chen, AN Nafziger, GL Drusano, L Ma, JS Bertino, Jr.. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese and extremely obese adults. Antimicrob Agents Chemother. 2006;50:1222-1227.
30. Sprandel KA, GL Drusano, DW Hecht, JC Rotschafer, LH Danziger, KA Rodvold. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diag Microbiol Infec Dis. 2006;55:303-309.
31. Lodise TP, BM Lomaestro, GL Drusano. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics. Pharmacotherapy 2006;26:1320-1332.
32. Hope WW, PA Warn, A Sharp, S Howard, M Kasai, A Louie, TJ Walsh, GL Drusano, DW Denning. Derivation of an *in vivo* drug-exposure breakpoint for flucytosine against *Candida albicans* and the impact of the minimum inhibitory concentration, growth rate and resistance genotype on the antifungal effect. Antimicrob Agents Chemother. 2006;50:3680-3688.
33. Gumbo T, GL Drusano, W Liu, L Ma, MR Deziel, MF Drusano, A Louie. Anidulofungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006;50:3695-3700.
34. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, **Drusano G**, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Grazziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, Kontoyiannis DP, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tudela JL, Rotstein C, Ruhnke M, Schuster M, Shoham S, Sia IG, Siebel N, Silviera F, Singh N, Sobel J, Solomkin JS, Sorrell TC, Steinbach WJ, Temesgen Z, Tortorano A, Vartivarian S, VerWeij P, Viscoli C, Viviani MA, Walker RC, Wheat JL, Wiley J, Williamson P, Wingard JR, Yu VL, Zaoutis T. [Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.](http://www.ncbi.nlm.nih.gov/pubmed/16983616) Clin Infect Dis. 2006;43:1031-1039.
35. Kao M, K Bush, R Barnewell, J Estep, FW Thalacker, GL Drusano, N Minton, S Chien, A Hemeryck, MF Kelley. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob Agents Chemother. 2006;50:3535-3542.
36. Lodise T, B Lomaestro, GL Drusano. Piperacillin/tazobactam for *Pseudomonas aeruginosa* infections: Clinical implications of an extended infusion dosing strategy. Clin Infect Dis. 2007;44:357-363.
37. Tam VH, A Louie, MR Deziel, W Liu, GL Drusano. The relationship between quinolone exposures and resistance amplification is characterized by an inverted-U: A new paradigm for optimizing pharmacodynamics to counter-select resistance. Antimicrob Agents Chemother. 2007;51:744-747.
38. Hope WW, GL Drusano, CB Moore, A Sharp, A Louie, TJ Walsh. The effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. 2006. Antimicob Agents Chemother. 2007;51:285-295.
39. Chen M, L Ma, GL Drusano, JS Bertino, AN Nafziger. Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther. 2006;80:531-538.
40. Ambrose PG, SM Bhavnani, CM Rubino, A Louie, T Gumbo, A Forrest, GL Drusano. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007;44:79-86.
41. Gumbo T, A Louie, W Liu, PG Ambrose, SM Bhavnani, D Brown, GL Drusano. Isoniazid’s bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007;195:194-201.
42. Hope WW, MJ Kruhlak, CA Lyman, R Petraitiene, V Petraitis, A Francesconi, M Kasai, D Mickiene, T Sein, J Peter, AM Kelaher, JE Hughes, MP Cotton, CJ Cotton, J Bacher, S Tripathi, L Bermudas, TK Maugel, PM Zerfas, JR Wingard, GL Drusano TJ Walsh. Pathogenesis of *Aspergillus fumigatus* and the kinetics of galctomannan in an *in vitro* model of early invasive pulmonary aspergillosis: Implications for antifungal therapy. J Infect Dis. 2007;195:455-466.
43. Tam VH, A Louie, TR Fritsche, M Deziel, W Liu, DL Brown, L Deshpande, R Leary, RN Jones, GL Drusano. Drug Exposure Intensity and Duration of Therapy’s Impact on Emergence of Resistance of *Staphylococcus aureus* to a Quinolone Antimicrobial. J Infect Dis. 2007;195:1818-1827.
44. Gumbo T, GL Drusano, W Liu, RW Kulawy, C Fregeau, V Hsu, A Louie. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007;51:968-974.
45. Hope WW, NL Seibel, CL Schwartz, A Arietta, P Flynn, A Shad, E Albano, JJ Keirns, DN Buell, T Gumbo, GL Drusano, TJ Walsh. Population pharmacokinetics of micafunginin pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother. 2007;51:3714-3719.
46. Hope WW, PA Warn, A Sharp, P Reed, B Keevil, A Louie, TJ Walsh, DW Denning, GL Drusano. Optimization of the dosage of flucytosine in combination with Amphotericin B for disseminated candidiasis: a pharmacodynamics rationale for reduced dosing. Antimicrob Agents Chemother 2007;51:3760-3762.
47. Lodise TP, R Pypstra, JB Kahn, BP Murthy, HC Kimko, K Bush, GJ Noel, GL Drusano. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother. 2007;51:2378-2387.
48. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis. 2007; 45 (Suppl 1):S89-95.
49. Landersdorfer CB, CM Kirkpatrick, M Kinzig-Schippers, JB Bulitta, U Holzgrabe, GL Drusano, F Sorgel. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob Agents Chemother. 2007; 51: 3290-3297.
50. Louie A, MR Deziel, W Liu, GL Drusano. Impact of Resistance Selection and Mutant Growth Fitness on the Relative Efficacies of Streptomycin and Levofloxacin for Plague Therapy. Antimicrob Agents Chemother. 2007; 51: 2661-2667.
51. Lodise TP, Jr., R Nau, M Kinzig, RN Jones, GL Drusano, F Sorgel. Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2007;58:445-452.
52. Lodise TP, Jr., M Kinzig-Schippers, GL Drusano, U Loos, F Vogel, J Bullita, M Hinder, F Sorgel. Use of Population Pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Antimicrob Agents Chemother. 2007

|  |  |
| --- | --- |
|  |  |

1. Heine HS, A Louie, F Sorgel, J Bassett, L Miller, LJ Sullivan, M Kinzig-Schippers, GL Drusano. Comparison of two different protein synthesis inhibitor antibiotics for the therapy of *Yersinia pestis* delivered by aerosol challenge in a mouse model of pneumonic plague. J Infect Dis. 2007;196:782-787.
2. Sakka SG AK Glauner; J Bulitta, M Kinzig-Schippers, W Pfister, GL Drusano, F Sorgel. Population pharmacokinetics and pharmacodynamics of continuous vs. short-term infusion of imipenem/cilastatin in critically ill patients: a randomized, controlled trial. Antimicrob Agents Chemother. 2007; 51: 3304-3310.
3. Drusano GL, PG Ambrose, SM Bhavnani, JS Bertino, AN Nafziger, A Louie. Back to the future: Using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007; 45:753-760.
4. Bullita JB, SB Duffull, M Kinzig-Schippers, U Holzgrabe, U Stephan, GL Drusano, F Sorgel. Population pharmacokinetics and pharmacodynamics of piperacillin: systematic comparison of cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 2007; 51: 2497-2507.
5. Parker MM, Gordon D, Reilly A, Horowitz HW, Waters M, Bennett R, Hallack R, Smith J, Lamson D, Aydemir A, Dvali N, Agins BD, Drusano GL, Taylor J; Resistance Study Group. [Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naïve, HIV-infected individuals in New York State.](http://www.ncbi.nlm.nih.gov/pubmed/17919091) AIDS Patient Care STDS. 2007;21:644-652.
6. Gumbo T, A Louie, D Brown, PG Ambrose, SM Bhavnani, GL Drusano. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother. 2007; 51: 2329-2336.
7. Lodise TP, R Nau, M Kinzig, GL Drusano, RN Jones, F Sorgel. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J Antimicrob Chemother. 2007;60:1038-1044.
8. Ambrose PG, A Forrest, WA Craig, CM Rubino, SM Bhavnani, GL Drusano, HS Heine. Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine-Bacillus anthracis Inhalation Infection Model. Antimicrob Agents Chemother. 2007; 51:4351-4355.
9. Louie A, DL Brown, W Liu, RW Kulawy, MR Deziel, GL Drusano. In Vitro Infection Model Characterizing the Effect of Efflux Pump Inhibition on Prevention of Resistance to Levofloxacin and Ciprofloxacin in *Streptococcus pneumoniae*. Antimicrob Agents Chemother. 2007;51:3988-4000.
10. Rubino CM, L Ma, SM Bhavnani, J Korth-Bradley, J Speth, E Ellis-Grosse, KR Rodvold, PG Ambrose, GL Drusano. Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation. Antimicrob Agents Chemother. 2007;51:4085-4089.
11. Gumbo T, A Louie, MR Deziel, W Liu, LM Parsons, M Salfinger, GL Drusano. Concentration-dependent *Mycobacterium tuberculosis* killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-3788.
12. Gumbo T, J Hiemenz, L Ma, JJ Keirns, D Buell, GL Drusano. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis. 2008;60:329-331.
13. Lodise TP, B Lomaestro, J Graves, GL Drusano. Larger vancomycin doses are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52:1330-1336.
14. Ambrose PG, JB Anon, SM Bhavnani, OO Okusanya, RN Jones, MR Paglia, JB Kahn, GL Drusano. [Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis.](http://www.ncbi.nlm.nih.gov/pubmed/18313879) Diagn Microbiol Infect Dis. 2008;61:13-20.
15. Hope WW, D Mickiene, V Petraitis, R Petraitiene, AM Kelaher, JE Hughes, JM Cotton, J Bacher, JJ Keirns, D Buell, G Heresi, Benjamin DK Jr., AH Groll, GL Drusano, TJ Walsh. The pharmacokinetics and pharmacodynamics of micafungin in experimental Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163-171.
16. Louie A, HS Heine, K Kim, DL Brown, B VanScoy, W Liu, M Kinzig-Schippers, F Sörgel, GL Drusano. Use of an in vitro model of Bacillus anthracis infection to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance. Antimicrob Agents Chemother. 2008;52:2486-2496.
17. Bhavnani SM, A Forrest, JP Hammel, GL Drusano, Rubino CM, Ambrose PG. Pharmacokinetics-pharmacodynamics of quinolones against *Streptococcus pneumonia* in patients with community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;62:99-101.
18. [Lodise TP Jr](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lodise%20TP%20Jr%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), M [Gotfried](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gotfried%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), S [Barriere](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Barriere%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), GL [Drusano](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Drusano%20GL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus). Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2008;52:2300-2304.
19. [Beauchemin CA](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Beauchemin%20CA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), JJ [McSharry](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22McSharry%20JJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus),GL [Drusano](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Drusano%20GL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), JT [Nguyen](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Nguyen%20JT%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), GT [Went](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Went%20GT%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), RM [Ribeiro](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ribeiro%20RM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), AS. Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol. 2008;254:439-
451.
20. Drusano GL, OO Okusanya, A Okusanya, B Van Scoy, DL Brown, R Kulawy, F Sörgel, HS Heine, A Louie. Is 60 Days of Ciprofloxacin Administration Necessary for Post-Exposure Prophylaxis for Bacillus anthracis? Antimicrob Agents Chemother. 2008;52:3973-3979.

208. Drusano GL, W Liu, DL Brown, LB Rice, A Louie. Impact of Short Course Quinolone Therapy on Sensitive and Resistant Populations of *Staphylococcus aureus*. J Infect Dis 2009;199:219-226.

1. [McSharry JJ, MR Deziel, K Zager, Q Weng, GL Drusano.](http://www.ncbi.nlm.nih.gov/pubmed/18852271?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Pharmacodynamics of Cidofovir for Vaccinia Virus Infection in an in vitro Hollow Fiber Infection Model (HFIM) System. Antimicrob Agents Chemother 2009;53:129-35.
2. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, Incerpi S, Drusano GL, Davis FB, Davis PJ. [L-Thyroxine vs. 3,5,3'-Triiodo-L-Thyronine and Cell Proliferation: Activation of Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase.](http://www.ncbi.nlm.nih.gov/pubmed/19158403?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Am J Physiol Cell Physiol. 2009;296:C980-991.
3. Scaglione F, S Esposito, S Leone, V Lucini, M Panacci, L Ma, GL Drusano. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Resp J. 2009;34:394-400.
4. Landersdorfer CB, M Kinzig, FF Hennig, JB Bulitta, U Holzgrabe, GL Drusano, F Sorgel, J Gusinda. Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation. Antimicrob Agents Chemother. 2009; 53:2074-2081.
5. Drusano GL, W Liu, C Fregeau, R Kulawy, A Louie. Differing effect of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance on wild-type Pseudomonas aeruginosa PA01 and its isogenic MexAB efflux pump over-expressed mutant. Antimicrob Agents Chemother. 2009;53:2266-2273.
6. McSharry JJ, Q Weng, A Brown, R Kulawy, GL Drusano. Prediction of the pharmacodynamically-linked variable of oseltamivir carboxylate for Influenza A virus using an i*n vitro* hollow fiber infection model system. Antimicrob Agents Chemother. 2009;53:2375-2381.
7. Lodise TP, N Patel, B Lomaestro, KA Rodvold, GL Drusano. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49:507-514.
8. Louie A, C Fregeau, W Liu, R Kulawy, GL Drusano. [Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid (ELF) targets.](http://www.ncbi.nlm.nih.gov/pubmed/19364849?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Antimicrob Agents Chemother. 2009;53:3325-3330.
9. Rodvold KA, DP. Nicolau, TP Lodise, M Khashab, G Noel, JB Kahn, M Gotfried, SA Murray, S Nicholson, S Laohavaleeson, PR Tessier, G.L. Drusano. Identifying Exposure Targets for the Treatment of Staphylococcal Pneumonia with Ceftobiprole. Antimicrob Agents Chemother. 2009;53:3294-3301.
10. Landersdorfer CB, CM Kirkpatrick, M Kinzig, JB Bulitta, U Holzgrabe, GL Drusano, F Sörgel. [Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid](http://www.ncbi.nlm.nih.gov/pubmed/19564368?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum). Antimicrob Agents Chemother. 2009; 53:3902-3907.
11. van den Anker JN, P Pokorna, M Kinzig-Schippers, J Martinkova, R de Groot, GL Drusano, F Sorgel. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother. 2009; 53:3871-3879.
12. Drusano GL, OO Okusanya, AO Okusanya, B van Scoy, DL Brown, C Fregeau, R Kulawy, M Kinzig, F Sörgel, HS Heine, A Louie. Impact of spore biology on the rate of kill and suppression of resistance in *Bacillus anthracis.* Antimicrob Agents Chemother. 2009; 53:4718-4725.
13. Hope WW, GL Drusano. [Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.](http://www.ncbi.nlm.nih.gov/pubmed/19673971?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=5) Clin Microbiol Infect. 2009;15:602-612.
14. Bulitta JB, SB Duffull, CB Landersdorfer, M Kinzig, U Holzgrabe, U Stephan, GL Drusano, F Sörgel. [Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.](http://www.ncbi.nlm.nih.gov/pubmed/19748423?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=5) Diagn Microbiol Infect Dis. 2009;65:130-141.
15. Drusano GL. How many steps along the path is too far? Clin Infect Dis. 2010. 50:37-39.
16. Bhavnani SM, CM Rubino, PG Ambrose, TJ Babinchak, JM Korth-Bradley, GL Drusano. Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. Antimicrob Agents Chemother. 2010;54:1207-1212.
17. Patel N, MH Scheetz, GL Drusano, TP Lodise. [Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.](http://www.ncbi.nlm.nih.gov/pubmed/19858253?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=4) Antimicrob Agents Chemother. 2010;54:460-465.
18. Bulitta JB, CB Landersdorfer, SJ Hüttner, GL Drusano, M Kinzig, U Holzgrabe, U Stephan, F Sörgel. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother.2010;54:1275-1282.
19. BhavnaniSM, CM Rubino, PG Ambrose, GL Drusano. Relationship between daptomycin exposure and the probability of a creatine phosphokinase elevation as determined using data from a randomized trial for the treatment of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50:1568-1574.
20. Moriyama B, SA Henning, R Childs, SM Holland, VL Anderson, JC Morris, WH Wilson, GL Drusano, TJ Walsh. [High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.](http://www.ncbi.nlm.nih.gov/pubmed/20371747) Ann Pharmacother. 2010;44:939-945.
21. Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R, Drusano GL. [The combination of meropenem and levofloxacin is synergistic with respect to both *Pseudomonas aeruginosa* kill rate and resistance suppression](http://www.ncbi.nlm.nih.gov/pubmed/20368395). Antimicrob Agents Chemother. 2010;54:2646-2654.
22. Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL. [Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance](http://www.ncbi.nlm.nih.gov/pubmed/20308371). Antimicrob Agents Chemother. 2010;54:2638-2645.
23. Drusano GL, C Fregeau, W Liu, DL Brown, A Louie. Impact of Burden on Granulocyte Clearance of Bacteria in a Mouse Thigh Infection Model. Antimicrob Agents Chemother. 2010;54:4368-4372.
24. Brown AN, McSharry JJ, Weng Q, Driebe EM, Engelthaler DM, Sheff K, Keim PS, Nguyen J, Drusano GL. An In Vitro System for Modeling Influenza A Virus Resistance under Drug Pressure. Antimicrob Agents Chemother. 2010;54:3442-3450.
25. Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, Louie A. The Combination of Rifampin plus Moxifloxacin is Synergistic for Resistance Suppression, but is Antagonistic for Cell Kill for *Mycobacterium tuberculosis* as Determined in a Hollow Fiber Infection Model. mBio 1:3 e00139-10; Published 10 August 2010.
26. Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, Drusano GL, Bertino JS Jr. [Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.](http://www.ncbi.nlm.nih.gov/pubmed/20851549) Diagn Microbiol Infect Dis. 2010;68:251-258.
27. Drusano GL. [Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.](http://www.ncbi.nlm.nih.gov/pubmed/21115453) J Antimicrob Chemother 2010;65 (Suppl 4 iv):33-39.
28. Patel N, Scheetz MH, Drusano GL, Lodise TP. [Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success.](http://www.ncbi.nlm.nih.gov/pubmed/20736235) J Antimicrob Chemother. 2010;65):2285-2290.
29. Ambrose PG, SM Bhavnani, EJ Ellis-Grosse, GL Drusano. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: Look before you leap! Clin Infect Dis 2010;51(Suppl):S103-S110.
30. Louie A, HS Heine, B Vanscoy, A Eichas, K Files, S Fikes, DL Brown, W Liu, M Kinzig-Schippers, F Sörgel, GL Drusano. [Use of an In Vitro Pharmacodynamic Model to Derive a Moxifloxacin Regimen that Optimizes Kill of *Yersinia pestis* and Prevents Emergence of Resistance.](http://www.ncbi.nlm.nih.gov/pubmed/21115791) Antimicrob Agents Chemother. 2011;55:822-830.
31. Lodise T and GL Drusano. Pharmacokinetics and pharmacodynamics: Optimal antimicrobial therapy in the intensive care unit. Crit Care Clin 2011;27:1-18.
32. Brown AN, JB Bulitta, JJ McSharry, Q Weng, JR Adams, R Kulawy, GL Drusano.
The Effect of Half-Life on the Pharmacodynamic Index of Zanamivir Against Influenza Virus as Delineated by a Mathematical Model. Antimicrob Agents Chemother. 2011;55:1747-1753.
33. Brown AN, JJ McSharry, Q Weng, JR Adams, R Kulawy, GL Drusano. Zanamivir, at 600 mg Twice Daily, Inhibits Oseltamivir–Resistant 2009 pandemic H1N1 Influenza Virus in an in vitro Hollow Fiber Infection Model System. Antimicrob Agents Chemother. 2011;55:1740-46.
34. Lodise TP, F Sörgel, B Mason, D Melnick , M Kinzig GL Drusano. Penetration of Meropenem into Epithelial Lining Fluid in Intubated Patients with Nosocomial Pneumonia. Antimicrob Agents Chemother. 2011;55:1606-1610.
35. Patel N, Pai MP, Rodvold K, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: We can’t get there from here. Clin Infect Dis. 2011;52:969-974.
36. Patel N, K. Cardone, DW Grabe, S Meola, C Hoy, H Manley, GL Drusano, TP Lodise. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice weekly hemodialysis. Antimicrob Agents Chemother. 2011;55:1677-1683.
37. Lin H-Y, Landersdorfer CB, London D, Meng R, Lim C-U, Lin C, Lin S, Tang H-Y, Brown D, Van Scoy B, Kulawy R, Queimado L, Drusano GL, Louie A, Davis FB, Mousa SA, Davis PJ. (2011) Pharmacodynamic Modeling of Anti-Cancer Activity of Tetraiodothyroacetic Acid in a Perfused Cell Culture System. PLoS Comput Biol 7(2): e1001073. doi:10.1371/journal.pcbi.1001073.
38. Cardone KE, TP Lodise, N Patel, CD Hoy, S Meola, HJ Manley, GL Drusano, DW Grabe. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Clin J Amer Soc Neph. 2011;6:1-8.
39. Drusano GL, A Louie. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother. 2011; 55:2528-2531.
40. Mouton JW, PG Ambrose, R Canton, GL Drusano, S Harbarth, A Macgowan, U Theuretzbacher, J Turnidge. [Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.](http://www.ncbi.nlm.nih.gov/pubmed/21440486) Drug Resis Updat. 2011; 14:107-117.
41. Mortensen NP, Fowlkes JD, Maggart M, Doktycz MJ, Nataro JP, Drusano G, Allison DP. [Effects of sub-minimum inhibitory concentrations of ciprofloxacin on enteroaggregative Escherichia coli and the role of the surface protein dispersin.](http://www.ncbi.nlm.nih.gov/pubmed/21570813) Int J Antimicrob Agents. 2011;38:27-34.
42. Drusano GL, B Vanscoy, W Liu, S Fikes, D Brown, A Louie. [Saturability of Granulocyte Kill of Pseudomonas aeruginosa in a Murine Model of Pneumonia.](http://www.ncbi.nlm.nih.gov/pubmed/21422203) Antimicrob Agents Chemother. 2011; 55:2693-2695.
43. Louie A, B VanScoy, W Liu, R Kulawy, D Brown, HS Heine, GL Drusano. Comparative efficacies, of candidate antibiotics against *Yersinia pestis* in an *in vitro* pharmacodynamics model. Antimicrob Agents Chemother. 2011; 55:2623-2628.
44. [Patel N](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Patel%20N%22%5BAuthor%5D), MP [Pai](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pai%20MP%22%5BAuthor%5D), KA [Rodvold](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rodvold%20KA%22%5BAuthor%5D), B [Lomaestro](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lomaestro%20B%22%5BAuthor%5D), GL [Drusano](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Drusano%20GL%22%5BAuthor%5D), TP [Lodise](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lodise%20TP%22%5BAuthor%5D). Vancomycin: We can’t get there from here. Clin Infect Dis 2011;52:969-974.
45. Louie A, DS Stein, JZ Zack, W Liu, H Conde, C Fregeau, BD VanScoy, GL Drusano. [Dose Range Evaluation of Mycograb C28Y Variant, a Human Recombinant Antibody Fragment to Heat Shock Protein 90, In Combination with Amphotericin B-Desoxycholate for the Treatment of Murine Systemic Candidiasis.](http://www.ncbi.nlm.nih.gov/pubmed/21502626) Antimicrob Agents Chemother. 2011;55:3295-3304.
46. Louie A, Liu W, Kulawy R, Drusano GL. [In Vivo Pharmacodynamics of Torezolid Phosphate (TR-701), a New Oxazolidinone Antibiotic, against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus In a Mouse Thigh Infection Model.](http://www.ncbi.nlm.nih.gov/pubmed/21502615) Antimicrob Agents Chemother. 2011;55:3453-3460.
47. Drusano GL, TP Lodise, D Melnick, W Liu, A Oliver, A. Mena, B. Van Scoy, A Louie. Meropenem penetration into epithelial lining fluid in mice and men and delineation of exposure targets. Antimicrob Agents Chemother. 2011; 55:3406-3412.
48. Drusano GL, N Sgambati, A Eichas, D Brown, R Kulawy, A Louie. Effect of administering moxifloxacin plus rifampin against *Mycobacterium tuberculosis* 7 of 7 Days versus 5 of 7 Days in an *in Vitro* pharmacodynamic system. mBio. 2011 Jul 12;2:e00108-11.
49. McSharry JJ, GL Drusano. Antiviral pharmacodynamics in hollow fibre bioreactors. Antivir Chem Chemother. 2011;21:183-192.
50. Butterfield J, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP. [Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors that Influence Protein Binding.](http://www.ncbi.nlm.nih.gov/pubmed/21670191) Antimicrob Agents Chemother. 2011.;55:4277-4282.
51. Lodise TP, GL Drusano, JM Butterfield, J Scoville, M Gotfried, KA Rodvold. [Penetration of vancomycin into epithelial lining fluid in healthy volunteers.](http://www.ncbi.nlm.nih.gov/pubmed/21911567) Antimicrob Agents Chemother. 2011;55:5507-5511.
52. Drusano GL. What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia? J Antimicrob Chemother. 2011;suppl 3:iii61-iii67.
53. Drusano GL, W Liu, R Kulawy, A Louie. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother. 2011 Nov;55(11):5300-5.
54. Drusano GL, RA Bonomo, N Bahniuk, JB Bulitta, B van Scoy, H Defiglio, S Fikes, D Brown, SM Drawz, R Kulawy, A Louie. [Resistance Emergence Mechanism and Mechanism of Resistance Suppression by Tobramycin for Cefepime for Pseudomonas aeruginosa.](http://www.ncbi.nlm.nih.gov/pubmed/22005996) Antimicrob Agents Chemother. 2012;56:231-242.
55. Louie A, M Castanheira, W Liu, C Grasso, RN Jones, G Williams, I Critchley, D Thye, D Brown, B Vanscoy, R Kulawy, GL Drusano. [Pharmacodynamics of β-lactamase Inhibition by NXL104 in Combination with Ceftaroline, Examining Organisms with Multiple Types of β-lactamases.](http://www.ncbi.nlm.nih.gov/pubmed/22024819) Antimicrob Agents Chemother. 2012 Jan;56:258-270.
56. Louie A, BD Vanscoy, HS Heine 3rd, W Liu, T Abshire, K Holman, R Kulawy, DL Brown, GL Drusano. [Differential Effect of Linezolid and Ciprofloxacin on Toxin Production by Bacillus anthracis In an In Vitro Pharmacodynamic System.](http://www.ncbi.nlm.nih.gov/pubmed/22064542) Antimicrob Agents Chemother. 2012;56:513-517.
57. Cardone KE, DW Grabe, RW Kulawy, R Daoui, J Roglieri, S Meola, GL Drusano, TP Lodise. [Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis](http://www.ncbi.nlm.nih.gov/pubmed/22083473). Antimicrob Agents Chemother. 2012 Feb;56(2):725-30. doi: 10.1128/AAC.05515-11. Epub 2011 Nov 14.
58. Nicasio AM, JB Bulitta, TP Lodise, RE D'Hondt, R Kulawy, A Louie, GL Drusano. [Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow fiber infection model.](http://www.ncbi.nlm.nih.gov/pubmed/22083484) Antimicrob Agents Chemother. 2012;56(2):682-6. doi: 10.1128/AAC.05664-11. Epub 2011 Nov 14.
59. Louie A, B vanScoy, D Brown, HS Heine, GL Drusano. Impact of spores on the comparative efficacies of five antibiotics For the treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model. Antimicrob Agents Chemother. 2012;56:1229-1239.
60. Ambrose PG, J Hammel, S Bhavnani, C Rubino, E Ellis-Grosse, GL Drusano. Frequentist and Bayesian pharmacometric-based approach to facilitate critically needed new antibiotic development: Overcoming lies, damn lies and statistics. Antimicrob Agents Chemother. 2012 Mar;56(3):1466-70. doi: 10.1128/AAC.01743-10. Epub 2011 Dec 12.
61. Brown AN, JJ McSharry, JR Adams, R Kulawy, RJ Barnard, W Newhard, A Corbin, DJ Hazuda, A Louie, GL Drusano. [Pharmacodynamic Analysis of a Serine Protease Inhibitor (MK-4519) on Hepatitis C Virus using a Novel In Vitro Pharmacodynamic System.](http://www.ncbi.nlm.nih.gov/pubmed/22155837) Antimicrob Agents Chemother. 2012;56:1170-1181.
62. Drusano GL. Early endpoints for ABSSSI. Antimicrob Agents Chemother. 2012 May;56(5):2221-2. doi: 10.1128/AAC.00157-12. Epub 2012 Feb 6.
63. Martinez M, M Papich, GL Drusano. Dosing Regimen Matters: The Importance of Early Intervention and Rapid Attainment of the PK/PD Target. Antimicrob Agents Chemother. 2012;56:2795-2805.
64. Ambrose PG, Drusano GL, Craig WA. [In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.](http://www.ncbi.nlm.nih.gov/pubmed/22431852) Clin Infect Dis. 2012;54 Suppl 3:S220-228.
65. Ambrose PG, Bhavnani SM, Dudley MN, Ellis-Grosse E, Rubino CM, Drusano GL. [New EMA guideline for antimicrobial development.](http://www.ncbi.nlm.nih.gov/pubmed/22459079) Lancet Infect Dis. 2012 Apr;12(4):265-266.
66. V. Balasubramanian, S Solapure, S Gaonkar, KN Mahesh Kumar, RK Shandil, Abhijeet Deshpande, N. Kumar, KG Vishwas, V. Panduga, J. Reddy, S. Ganguly, A. Louie, G. Drusano. Effect of Co-administration of Moxifloxacin and Rifampin on Mycobacterium tuberculosis in a Murine Aerosol Infection Model. Antimicrob Agents Chemother 2012;56:3054-3057.
67. Felton T, W Hope, B Lomaestro, J Butterfield, A Kwa, G Drusano, T Lodise. [Population pharmacokinetics of extended infusion Piperacillin/Tazobactam in hospitalized patients with nosocomial infections.](http://www.ncbi.nlm.nih.gov/pubmed/22585219) Antimicrob Agents Chemother. 2012 ;56:4087-4094.
68. Landersdorfer CB, JB Bulitta, CMJ Kirkpatrick, M Kinzig, U Holzgrabe, GL Drusano, U Stephan, F Sörgel. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrob Agents Chemother. 2012;56:5713-5723.
69. Drusano GL, TP Lodise. [Editorial commentary: saving lives with optimal antimicrobial chemotherapy.](http://www.ncbi.nlm.nih.gov/pubmed/23074312) Clin Infect Dis. 2013;56:245-247.
70. Heine HS, Louie A, Adamovicz JJ, Amemiya K, Fast RL, Miller L, Opal SM, Palardy J, Parejo NA, Sörgel F, Kinzig-Schippers M, Drusano GL. Natural History of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice. Antimicrob Agents Chemother. 2013;57:2010-2015.
71. Louie A, W Liu, S Fikes, D Brown, GL Drusano. Impact of meropenem in combination with tobramycin in a murine model of *Pseudomonas aeruginosa* pneumonia. Antimicrob Agents Chemother. 2013;57:2788-2792.
72. Louie A, B Vanscoy, W Liu, R Kulawy, GL Drusano. [Hollow Fiber Pharmacodynamic Studies and Mathematical Modeling to Predict the Efficacy of Amoxicillin for Anthrax Postexposure Prophylaxis in Pregnant Women and Children.](http://www.ncbi.nlm.nih.gov/pubmed/24041894) Antimicrob Agents Chemother. 2013;57:5946-5960.
73. Neely M, G Youn, B Jones, R Jelliffe, G Drusano, K Rodvold, T Lodise. Are vancomycin troughs adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58:309-316.
74. [Hendricks](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hendricks%20KA%5Bauth%5D) KA, [ME Wright](http://www.ncbi.nlm.nih.gov/pubmed/?term=Wright%20ME%5Bauth%5D), [SV Shadomy](http://www.ncbi.nlm.nih.gov/pubmed/?term=Shadomy%20SV%5Bauth%5D), et al and the Workgroup on Anthrax Clinical Guidelines. Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults. Emerg Infect Dis. Feb 2014; 20(2): e130687.
75. Perez F, Arias CA, Bush K, Drusano GL, Lolans K, Munoz-Price LS, Nicolau DP, Queenan AM, Rice LB, Segreti J, Shlaes DM, Weinstein RA, Bonomo RA. In Memoriam: John P. Quinn, MD. Clin Infect Dis. 2014;58:748-750.
76. Heine H, A Louie, J Adamovicz, K Amemiya, R Fast, L Miller, S Opal, J Palardy, N Parejo, F Sörgel, M Kinzig-Schippers, GL Drusano. Evaluation of Imipenem for the Prophylaxis and Therapy of Yersinia pestis Delivered by Aerosol in a Mouse Model of Pneumonic Plague. Antimicrob Agents Chemother. 2014;58:3276-3284.
77. Coleman K, P Levasseur, AM Girard, M Borgonovi, C Miossec, H Merdjan, G Drusano, D Shlaes, WW Nichols. [The activity of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.](http://www.ncbi.nlm.nih.gov/pubmed/24687507) Antimicrob Agents Chemother. 2014;58:3366-3372.
78. Roberts JA, MH Abdul-Aziz, J Lipman, JW Mouton, AA Vinks, TW Felton, WW Hope, A Farkas, MN Neely, JJ Schentag, G Drusano, OR Frey, U Theuretzbacher, JL Kuti. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014 Jun;14:498-509.
79. Lodise TP, Drusano GL, Lazariu V, El-Fawal N, Evans A, Graffunder E, Stellrecht K, Mendes RE, Jones RN, Cosler L, McNutt LA. [Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin.](http://www.ncbi.nlm.nih.gov/pubmed/24840624)  J Antimicrob Chemother. 2014 Sep;69:2547-2555.
80. T.P. Lodise; G.L. Drusano; E. Zasowski; A. Dihmess; V. Lazariu; L. Cosler; L.A. McNutt. Vancomycin Exposure in Patients with MRSA Bloodstream Infections: How much is enough? Clinical Infectious Diseases 2014;59:666-675.
81. Drusano GL, W Liu, S Fikes, R Cirz, N Robbins, S Kurhanewicz, J Rodriquez, D Brown, D Baluya, A Louie. [Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a](http://www.ncbi.nlm.nih.gov/pubmed/24760199) murine pneumonia model. J Infect Dis 2014;210:1319-1324.
82. Lodise TP and GL Drusano. Use of pharmacokinetics/pharmacodynamics systems analyses to inform dose selection for tedizolid phosphate. Clin Infect Dis. 2014. 58 (S1);S28-34.
83. Drusano GL, M Neely, M Van Guilder, A Schumitzky, D Brown, S Fikes, C Peloquin, A Louie. Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis. PLoS One. 2014 Jul 8;9(7):e101311.
84. Louie A, W Liu, M VanGuilder, MN Neely, A Schumitzky, R Jelliffe, S Fikes, S Kurhanewicz, N Robbins, D Brown, Dodge Baluya, GL Drusano. Meropenem plus Levofloxacin is Synergistic for the Therapy of *Pseudomonas aeruginosa* as Tested in a Murine Model of Pneumonia. J Infect Dis. 2015;211:1326-1333.
85. Louie A, Boyne MT 2nd, Patel V, Huntley C, Liu W, Fikes S, Kurhanewicz S, Rodriquez J, Robbins N, Brown D, Baluya D, Drusano GL. [Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States.](http://www.ncbi.nlm.nih.gov/pubmed/25385113) Antimicrob Agents Chemother. 2015;59:622-632.
86. Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Drusano GL, Khariton T, Friedland HD, Riccobene TA, Ambrose PG. [Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.](http://www.ncbi.nlm.nih.gov/pubmed/25367904) Antimicrob Agents Chemother. 2015;59:372-380.
87. Brown AN, JR Adams, DL Baluya, GL Drusano. Pharmacokinetic Determinants of Virological Response to Raltegravir in the In Vitro Pharmacodynamic Hollow-Fiber Infection Model System. Antimicrob Agents Chemother 2015;59: 3771-3777.
88. Theuretzbacher U, Ambrose PG, MacGowan AP, Andes DR, Sörgel F, Derendorf H, Mouton JW, Drusano GL, Tulkens PM, Dudley MN, Cars O, Nation RL. In Memoriam: William A. Craig. Antimicrob Agents Chemother. 2015;59:2971.
89. Docobo-Pérez F, GL Drusano, A Johnson, J Goodwin, S Whalley, V Ramos-Martín, M Ballestero-Tellez, JM Rodriguez-Martinez, C Conejo, M van Guilder, J Rodríguez-Baño1, A Pascual, WW Hope. Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. Antimicrob Agents Chemother. 2015 Sep;59:5602-5610.
90. Brown AN, Drusano GL, Adams JR, Rodriquez JL, Jambunathan K, Baluya DL, Brown DL, Kwara A, Mirsalis JC, Hafner R, Louie A. [Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.](http://www.ncbi.nlm.nih.gov/pubmed/26530386) MBio. 2015 Nov 3;6(6). pii: e01741-15. doi: 10.1128/mBio.01741-15.
91. Drusano GL, A Louie, A MacGowan, and W Hope. Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping our Powder Dry-Part 1. Antimicrob Agents Chemother. 2015;60:1183-1193.
92. Drusano GL, W Hope, A MacGowan, A Louie. Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping our Powder Dry-Part 2. Antimicrob Agents Chemother. 2015;60:1194-1201.
93. BhavnaniSM, PG Ambrose, JP Hammel, CM Rubino, GL Drusano. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints to Support Risk versus Benefit Considerations. Antimicrob Agents Chemother. 2015;60:1600-1607.
94. Heine HS, Chuvala L, Riggins R, Cirz R, Cass R, Louie A, Drusano GL. Natural history of *Francisella tularensis* in aerosol-challenged BALB/c mice. Antimicrob Agents Chemother 2016;60:1834-1840.
95. Hope W, Drusano GL, Rex JH. Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimisation and demonstration of causality. J Antimicrob Chemother. 2016;71:3008-3019.
96. Gallegos KM, Drusano GL, D’Argenio DZ, Brown AN. Chikungunya Virus: In Vitro Response to Combination Therapy with Ribavirin and Interferon-α2a. J Infect Dis.2016;214:1192-1197.
97. Drusano GL. From lead optimization to NDA approval for a new antimicrobial: Use of pre-clinical effect models and pharmacokinetic/pharmacodynamics mathematical modeling. Bioorg Med Chem. 2016;24:6401-6408.
98. Drusano GL. Stepping off the resistance treadmill. Editorial: J Infect Dis. 2017 Jul 15;216(2):150-152.
99. Heine H, Shadomy S, Boyer A, Chuvala L, Riggins R, Kesterson A, Myrick J, Craig J, Gallegos-Candela M, Barr J, Hendricks K, Bower W, Walke H, Drusano GL. Evaluation of Combination Drug Therapy for Treatment of Antibiotic Resistant Inhalation Anthrax in a Murine Model. Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00788-17. doi: 10.1128/AAC.00788-17.2017.
100. Pomeroy JJ, Drusano GL, Rodriquez JL, Brown AN. [Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.](https://www.ncbi.nlm.nih.gov/pubmed/28882564) Antiviral Res. 2017 Sep 4;146:149-152. doi: 10.1016/j.antiviral.2017.09.001.
101. Drusano GL, Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo Torre CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C. Dilution factor of quantitative bacterial cultures obtained by bronchoalveolar lavage in patients with ventilator-associated bacterial pneumonia: Implications for optimal antimicrobial therapy. Ventilator-Associated Bacterial Pneumonia Study Group. 2017 Oct 16. pii: AAC.01323-17. doi: 10.1128/AAC.01323-17. Antimicrob Agents Chemother.
102. Drusano GL. Preclinical *in vitro* infection models. Current Opinion in Pharmacology 2017;36:100-106.
103. Brown, A.N., L. Liu,J. L. Rodriquez, L. Zhao, L. Schuster, E. Li2, G.P. Wang, M.N. Neely, W. Yamada, GL Drusano. Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). Scientific Reports 2017;7:14421. doi: 10.1038/s41598-017-15007-2.
104. Pires de Mello CP, Drusano GL, Adams JR, Shudt M, Kulawy R, Brown AN. [Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.](https://www.ncbi.nlm.nih.gov/pubmed/29079337) Eur J Pharm Sci. 2018 Jan 1;111:443-449. doi: 10.1016/j.ejps.2017.10.027. Epub 2017 Oct 25.
105. Sutaria D, Moya B, Green K, Kim TH, Tao X, Jiao Y, Louie A, Drusano G, Bulitta J. First penicillin-binding protein occupancy patterns of β-lactams and β-lactamase inhibitors in *Klebsiella pneumonia*. Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00282-18.
106. Louie A, Maynard M, Duncanson B, Nole J, Vicchiarelli M, Drusano GL. [Determination of the dynamically-linked indices of fosfomycin for *Pseudomonas aeruginosa* in the Hollow Fiber Infection Model (HFIM).](https://www.ncbi.nlm.nih.gov/pubmed/29581114) Antimicrob Agents Chemother. 2018 Mar 26. pii: AAC.02627-17. doi: 10.1128/AAC.02627-17.
107. Drusano GL, J Myrick, M Maynard, J Nole, B Duncanson, D Brown, S Schmidt, M Neely, CA Scanga, C Peloquin, A Louie. Linezolid Kills Acid Phase and Non-replicative Persister Phase *Mycobacterium tuberculosis* in a Hollow Fiber Infection Model. Antimicrobial Agents and Chemotherapy 2018 Jul 27;62(8). pii: e00221-18.
108. De Miranda Silva C, A Hajihosseini, J Myrick, J Nole, A Louie, S Schmidt, GL Drusano. Effect of Linezolid plus Bedaquiline against *Mycobacterium tuberculosis* in Log-Phase, Acid-Phase and Non-Replicating-Persister (NRP)-Phase in an *In vitro* Assay. Antimicrobial Agents and Chemotherapy 2018; 62. pii: e00856-18.
109. Pires de Mello C, G Drusano, A Kaushik, A Brown. Antiviral effects of clinically-relevant interferon-α and ribavirin regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM). Viruses. Viruses. 2018 Jun 9;10(6). pii: E317. doi: 10.3390/v10060317.
110. Louie A, Duncanson B, Myrick J, Maynard M, Nole J, Brown D, Schmidt S, Neely M, Scanga CA, Peloquin C, Drusano GL. [The Activity of Moxifloxacin against Acid-Phase and Non-Replicative Persister Phenotype Phase *Mycobacterium tuberculosis* in a Hollow Fiber Infection Model.](https://www.ncbi.nlm.nih.gov/pubmed/30249693) Antimicrob Agents Chemother. 2018;62. pii: e01470-18.
111. Drusano GL, Neely MN, Yamada WM, Duncanson B, Brown D, Maynard M, Vicchiarelli M, Louie A. [The combination of fosfomycin plus meropenem is synergistic for *Pseudomonas aeruginosa* PA01 in a Hollow Fiber Infection Model (HFIM).](https://www.ncbi.nlm.nih.gov/pubmed/30249700) Antimicrob Agents Chemother. 2018 ;62(12). pii: e01682-18.
112. Heinrichs MT, Drusano GL, Brown DL, Maynard MS, Sy SKB, Rand KH, Peloquin CA, Louie A, Derendorf H. [Dose Optimization of Moxifloxacin and Linezolid Against Tuberculosis Using Mathematical Modeling and Simulation.](https://www.ncbi.nlm.nih.gov/pubmed/30385322) Int J Antimicrob Agents. 2018 Oct 29. pii: S0924-8579(18)30304-2. doi: 10.1016/j.ijantimicag.2018.10.012. [Epub ahead of print]
113. de Miranda Silva C, Hajihosseini A, Myrick J, Nole J, Louie A, Schmidt S, Drusano GL. [Effect of Moxifloxacin plus Pretomanid against *Mycobacterium tuberculosis* in Log-phase, Acid-phase and Non-Replicating-Persister (NRP)-phase in an i*n vitro* assay.](https://www.ncbi.nlm.nih.gov/pubmed/30397058) Antimicrob Agents Chemother. 2018 Nov 5. pii: AAC.01695-18. doi: 10.1128/AAC.01695-18.
114. Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, Tao X, Wittau M, Tsuji BT, Zavascki AP, Shin BS, Drusano GL, Sörgel F, Landersdorfer CB. [Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.](https://www.ncbi.nlm.nih.gov/pubmed/29936678) Clin Pharmacokinet. 2019;58(2):143-156.
115. Drusano GL and Louie A. Breakpoint Determination when Multiple Organisms are Tested for Effect Targets. European Journal of Pharmaceutical Sciences. 2019 Jan 31;130:196-199. doi: 10.1016/j.ejps.2019.01.033. [Epub ahead of print]

**LETTERS:**

 1. Herrington, D., Drusano, G.L., Smalls, U., Standiford, H.C. False Elevation in Serum Creatinine Levels. JAMA 252:2962, December 7, 1984.

 2. Savarino, S.J., Rennels, M.B., Drusano, G.L. Pseudomonas meningitis therapy recommendation questioned. Pediatrics 83(4 Pt 2):632-633, April, 1989.

3. Bilello, JA and Drusano GL. Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease. J Infec Dis 1996; 173:1524-1526.

4. [Kees MG](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kees%20MG%22%5BAuthor%5D), TP [Lodise](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lodise%20TP%22%5BAuthor%5D), GL [Drusano](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Drusano%20GL%22%5BAuthor%5D). Determination of meropenem penetration into the lung from sparse data. [Antimicrob Agents Chemother.](http://www.ncbi.nlm.nih.gov/pubmed/22081725) 2011;55:5959-5961.

5. Brown AN, Gallegos KM, D'Argenio DZ, Drusano GL. Reply to Scagnolari et al. J Infect Dis. 2016 Dec 21. pii: jiw580. doi: 10.1093/infdis/jiw580.